| 000 | 01329 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516163948.0 | ||
| 264 | 0 | _c20151026 | |
| 008 | 201510s 0 0 eng d | ||
| 022 | _a1860-7187 | ||
| 024 | 7 |
_a10.1002/cmdc.201300311 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrett, Brendan | |
| 245 | 0 | 0 |
_aTargeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage? _h[electronic resource] |
| 260 |
_bChemMedChem _cOct 2013 |
||
| 300 |
_a1620-2 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aCyclic Nucleotide Phosphodiesterases, Type 6 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Interaction Domains and Motifs _xdrug effects |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aProto-Oncogene Proteins p21(ras) |
| 650 | 0 | 4 |
_aras Proteins _xantagonists & inhibitors |
| 700 | 1 | _aWang, Yuanxiang | |
| 700 | 1 | _aLi, Hong-Yu | |
| 773 | 0 |
_tChemMedChem _gvol. 8 _gno. 10 _gp. 1620-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cmdc.201300311 _zAvailable from publisher's website |
| 999 |
_c22999102 _d22999102 |
||